Lithos Health alternatives for product and operations teams

How should you build this shortlist?

A team shopping for a clinical API often starts with endpoints and pricing, then discovers operational boundaries during implementation. Start instead with the patient journey and the systems that own each part. Determine where intake is captured, where clinical information lives, how the patient communicates and how commercial subscriptions are managed. That map tells you whether an alternative is a direct replacement or a different architecture.

The shortlist below includes both modular clinical services and managed brand platforms. Those approaches can support similar customer experiences while leaving different work with your team. Read the white-label telehealth guide before comparing prices across categories. The evaluation should cover incidents, changes and support after launch, not only how quickly a developer can make a successful request in a sandbox.

Which alternative fits which buying question?

The following are evaluation routes, not claims that one vendor is universally best. Public-source review date: October 22, 2026. Confirm the current written scope before contracting.

When is TEHR a broader alternative to a clinical API?

TEHR is worth evaluating if your team wants brand software and administrative workflows supplied together with access to independent clinical services. Payments, subscriptions and AI-assisted intake are part of the platform proposition, with support scope agreed in a proposal. The flat subscription and flat transaction model carries 0% revenue share; request a scoped quote.

The strength is reducing the number of product and operational boundaries you must assemble. The tradeoff is that your team should confirm the implementation flexibility and service scope it actually needs. Ask TEHR to demonstrate the platform around your existing customer journey, including repeat orders and unresolved cases. Its operator history across DudeMeds, Peptiders, TellyMeds and FansMeds should inform a concrete plan rather than substitute for one.

When should Beluga be compared as a modular route?

Beluga describes direct integration, hosted intake and platform-partner paths. It is relevant when your team wants to preserve some components while changing where clinical services connect to the experience.

The strength is architectural choice; the tradeoff is the need to identify who operates every selected component. Ask whether your product, a hosted page or a partner platform owns each patient-facing step. Require examples of status updates, message handling and error recovery in the actual route being quoted. Avoid comparing the capabilities of a platform partner with the commercial terms of a direct API arrangement. The Beluga comparison makes those ownership and scope questions explicit.

When does MD Integrations fit the technical shortlist?

MD Integrations offers custom integration and a ready-made white-label path. Consider it if you want to evaluate the clinical service connection without assuming every customer-facing component must be rebuilt.

The strength is a choice between implementation approaches. The tradeoff is that clinical and commercial scope still need separate confirmation. Its FAQ excludes controlled-substance prescribing, so check program fit before planning around a general hormone category. Ask the implementation team to demonstrate follow-up messaging, status reconciliation and how your staff handle a patient who cannot follow the normal workflow. A convenient connection matters, but it should be tested against both clinical requirements and your ongoing operational capacity.

When is Cuvo a reasonable change of architecture?

Cuvo offers managed brand packages with published pricing and an included migration offer. It can be relevant when your engineering team would rather stop maintaining parts of the commercial and operational stack.

The strength is a more packaged implementation boundary. The tradeoff is that a broader replacement can require decisions about existing systems that already work. Identify what should be retained before buying a full build. Ask which integrations are supported in the selected plan and how an existing product would connect if you do not want a new storefront. Compare implementation deliverables and ongoing staff work together, rather than treating a setup fee as comparable to a per-visit API price in isolation.

When should Tessic’s managed platform be considered?

Tessic presents tiered brand software and managed infrastructure. Evaluate it when your team is deciding whether to purchase more of the operating environment rather than continue building around a clinical interface.

The strength is a defined package structure that can be mapped to requirements. The tradeoff is plan-dependent scope, especially when your existing product needs integrations or custom behavior. Ask the team to identify which parts of your workflow fit the standard configuration and which require a different tier or project. A managed environment can reduce integration ownership, but it should not force a valuable product experience into the wrong shape. Test the specific path your customers use, not an unrelated demo template.

When does CareValidate address an operational need?

CareValidate describes managed patient support and clinical operations. It is worth evaluating if the reason for reconsidering your architecture is the work required to coordinate people and services after the software connection is live.

The strength to test is service ownership. Ask who investigates a delayed result, routes a clinical question and keeps the patient informed when more than one organization is involved. The tradeoff is that the precise commercial and support terms require a scoped proposal; numerical public pricing was not established here. A broader service partner may be appropriate, but only if the contract names the tasks your team expects it to perform and the interfaces through which you can observe progress.

When should FUSE’s builder and embedding approach be evaluated?

FUSE describes SDK/API embedding and different levels of build assistance. Consider it when the product work you want to retain is narrower than a fully custom application, or when you want to configure more of the experience within a vendor environment.

The strength is flexibility in build involvement. The tradeoff is that a build tool does not define every live clinical or operational responsibility. Ask how a configured experience moves into production and what prerequisites remain. Model payment-based merchant charges separately from other potential costs, and resolve the inconsistent public DIY monthly figure in writing. Compare the actual ongoing engineering work and support ownership rather than assuming a self-service path is maintenance-free.

When does Healthie fit a practice-software strategy?

Healthie’s full web white-label option is an Enterprise software add-on. It may suit a team that wants to anchor its patient experience in practice software while separately arranging the clinical workforce and other operating relationships.

The strength is a software foundation around an existing care organization. The tradeoff is that you must supply or procure what the software agreement does not include. Ask how the branded experience connects to your provider and commercial systems, and what information remains in external interfaces. Do not compare an entry-level software subscription with a complete clinical-service price. This can be the right architecture for a staffed practice, but it is not automatically a replacement for a medical practice delivered through an API.

What should an API replacement test prove?

Create a small test pack around your real workflow. Include a normal encounter, a missing required field, a repeated event, a delayed fulfillment update and a patient question that needs escalation. Ask each vendor to show how your product detects the state, what action is permitted and how staff resolve it. Successful requests alone do not demonstrate an operable integration.

For a switch, inventory identifiers, clinical history, open orders, upcoming care and recurring payments. Lithos’s migration page describes staged transitions, which is useful evidence that continuity deserves its own project. Apply the same discipline to an outbound move: request the actual export and termination terms, then use the migration checklist to validate the new mapping. Keep product testing separate from clinical readiness and commercial cutover. The new architecture should make ownership clearer, not merely change the endpoint receiving your requests.

Who maintains the interface after launch?

Ask each modular-service candidate how changes to fields, events and clinical workflows are communicated and tested. Your product team needs a named owner for monitoring those changes and coordinating updates with operations. A successful initial integration does not settle that ongoing responsibility. Compare this retained maintenance with the configuration and change process offered by a managed platform before choosing the architecture that appears lighter on the first day.

What is the next useful step?

Compare two or three written scopes against the operating brief you developed. Use TEHR vs Lithos Health for the direct comparison, TEHR pricing for the commercial structure and a TEHR demo to test your own workflow. The resource library includes further implementation and procurement guides.

What else should you know?